ArticleJournal of neuro-oncology2026
Malignant transformation in IDH-mutant gliomas: clinical drivers and survival outcomes in a histologically defined cohort.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.Journal of neuro-oncology · 2026Article
- From Epigenetic Constraint to Evolutionary Escape: Cell-State Transitions and Selective Pressures During Malignant Transformation in Lower-Grade Gliomas.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The predictors and prognostic implications of malignant transformation (MT) in IDH-mutant gliomas remain incompletely defined. Prior studies have often included mixed IDH populations or relied on contrast enhancement as a surrogate for transformation, which is an unreliable marker of malignant progression. Methods: We retrospectively reviewed patients with recurrent IDH-mutant gliomas who underwent multiple surgical resections between 2009 and 2024 at a single tertiary center. Malignant transformation was defined as a pathologically confirmed increase in tumor grade between the initial and any subsequent surgery. Results: Among 124 patients identified, 73 (58.9%) experienced malignant transformation. Transformation patterns included grade 2–3 astrocytomas (19.4%), grade 2–3 oligodendrogliomas (18.9%), grade 3–4 astrocytomas (12.1%), and grade 2–4 astrocytomas (8.9%). Median time to transformation was 6.2 years for grade 2–3 astrocytomas, 8.8 years for grade 2–3 oligodendrogliomas, 5.7 years for grade 3–4 astrocytomas, and 4.3 years for grade 2–4 astrocytomas (p = 0.42). Malignant transformation was associated with significantly shorter progression-free survival (1.1 vs. 4.4 years; p < 0.0001) and overall survival following transformation (1.7 vs. 5.8 years; p < 0.0001). On multivariable analysis, 1p/19q codeletion (HR 0.35, 95% CI 0.20–0.62) and adjuvant radiotherapy (HR 0.48, 95% CI 0.27–0.83) were associated with reduced risk of transformation, whereas subventricular zone involvement was associated with increased risk (HR 1.9, 95% CI 1.01–3.58). Conclusion: These findings refine current understanding of the timing, risk factors, and prognostic impact of malignant transformation in IDH-mutant gliomas and underscore the need for molecularly informed strategies to improve risk stratification and guide targeted interventions.
Indexed as
Identifiers
41806156What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.